Gonorrhea Diagnostics Market - Forecast, 2022-2027

 The Gonorrhea Diagnostics Market is estimated to reach $13.6 billion by 2028, growing at a CAGR of 8.9% over the forecast period 2023-2028. Gonorrhea is a sexually transmitted infection afflicted by a bacterium that can affect both genders. Most often, gonorrhea impacts the urethra, rectum or throat. The recommended treatment for gonorrhea includes fluoroquinolone and ciprofloxacin. Cephalosporins, ceftriaxone (intramuscular) or cefixime (oral) are the recommended alternatives. However, recent audit data reveal other cephalosporins, including cefuroxime (intramuscular or often oral), that are currently being used to treat gonorrhea. Gonorrhea can also infect the cervix in females. Most frequently, gonorrhea is spread through vaginal, oral or anal intercourse. But after childbirth, newborns of infected mothers can contract the disease. Gonorrhea most frequently damages the eyes in infants. According to the Women’s Health & STIs article, for vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.



Gonorrhea Diagnostics Market Report Coverage


The report: “Gonorrhea Diagnostics Market – Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Gonorrhea Diagnostics Market.

By Type: Nucleic Acid Amplification, Gram Stain, Enzyme-linked Immunosorbent Assay, Gonorrhea Culture, Rapid Test and Others.

By Diagnostic Type: Flow Cytometry, Diagnostic Imaging, Gel Micro-droplets, Artificial Intelligence, Chromatography, Differential Light Scattering (DLS), Liposomes, Monoclonal Antibodies, Molecular Diagnostics Tests and Others.

By Treatment: Fluoroquinolone, Ciprofloxacin, Cephalosporins, Ceftriaxone, Cefixime, Cefuroxime and Others.

By End-user: Hospitals, Laboratory Testing, Diagnostic Centers, Clinics, Point-of-care Testing and Others.

By Geography: North America (the U.S., Canada and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia and New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).


Key Takeaways


  • Geographically, North America dominates the Gonorrhea Diagnostics Market in 2022, owing to the rising awareness about the disease.
  • The key factor anticipated to drive the Gonorrhea Diagnostics industry in the future is the engagement of multiple sex partners and rapidly changing lifestyles.
  • The growth rate of the Gonorrhea diagnostics market size is anticipated to be steady, owing to an increase in hospitals, commercial labs and improved diagnostic methods that are quicker and more cost-effective.
  • A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Gonorrhea Diagnostics Market Report.


Gonorrhea Diagnostics Market Segment Analysis – by Diagnostic Type:


Based on Diagnostic Type, Gonorrhea Diagnostics Market is further segmented into Flow Cytometry, Diagnostic Imaging, Gel Micro-droplets, Artificial Intelligence, Chromatography, Differential Light Scattering (DLS), Liposomes, Monoclonal Antibodies, Molecular Diagnostics Tests and Others. The Molecular Diagnostics segment held the largest share of the Gonorrhea diagnostics market in 2022, owing to the advantages associated with it such as ease of performing the procedure, high accuracy and cost for the performance. It is often necessary to use monoclonal antibody techniques to determine between gonorrhea and other illnesses that have overlapping symptoms, which helps in expanding the Gonorrhea Diagnostics market size.


However, the Flow Cytometry segment is anticipated to grow at the fastest CAGR of 9.5% over the forecast period 2023-2028. This is due to modern techniques such as artificial intelligence and diagnostic imaging, which are in the testing phases. Traditional methods of diagnosis are predicted to be replaced by newer technologies like flow cytometry for faster and more accurate illness detection and change the market scenario for the Gonorrhea Diagnostics industry in the future.


Gonorrhea Diagnostics Market Segment Analysis – by End-user:


Based on end-users, the Gonorrhea Diagnostics market is further segmented into hospitals, laboratory testing, diagnostic centers, clinics, point-of-care testing and others. The Point-of-care Testing segment held the largest share of the Gonorrhea diagnostics market in 2022, as the rates of gonococcal infection and associated costs of untreated infections continued to increase. According to the Centers for Disease Control (CDC), the rate of gonococcal infection has increased by 74% despite the availability of highly sensitive and specific laboratory-based molecular diagnostics tools for the detection of these Sexually Transmitted Infections (STIs).


However, the Laboratory Testing segment is anticipated to grow at the fastest CAGR of 9.3% over the forecast period 2023-2028, as most of the cases of diagnostic testing are carried out in the labs, which is anticipated to further fuel the Gonorrhea Diagnostics market.


Gonorrhea Diagnostics Market Segment Analysis – by Geography:


Based on Geography, the North American Gonorrhea Diagnostics Market accounted for 37% of the revenue share in 2022, owing to the well-developed healthcare infrastructure and favorable government policies regarding the diagnosis and treatment of Sexually Transmitted Diseases (STD). According to the Centers for Disease Control (CDC), there are around 400,000 cases of gonorrhea reported each year in the U.S. The high awareness level about the disease and favorable reimbursement policies are the factors anticipated to expand the Gonorrhea diagnostics market size in the region.


However, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period 2023-2028, owing to the increasing cases of the disease in the region and the number of unmet demands in the market for efficient diagnoses and treatments.


Gonorrhea Diagnostics Market Drivers


Increasing Rates of Sexually Transmitted Infections (STIs):


    The Gonorrhea Diagnostics market for Sexually Transmitted Diseases (STD) testing is growing as a result of increased public awareness and patient education. Additionally, it is projected that an expansion of government initiatives, an improvement in patient awareness through education programs and an increase in STI prevalence internationally would fuel market expansion. The prevalence and incidence of STIs have accelerated. According to WHO, more than 1 million Sexually Transmitted Infections (STIs) are acquired every day worldwide, the majority of which are asymptomatic.


    The Rising Prevalence and Awareness of the Disease:


    Gonorrhea prevalence rates are rising as a result of a number of factors, including increased public awareness, better access to healthcare, diagnostic test availability, patterns of resistance, reporting practices and others. Although gentamicin should not be used as the first line of treatment for gonorrhea, it may still be beneficial for some people. They may be individuals with isolated genital infections, people who are allergic to or intolerant to ceftriaxone or ones who have an infection that is resistant to ceftriaxone. In the past, men were more likely than women to contract gonorrhea and get treated through chromatography diagnostics. Over the past few years, the prevalence rate of gonorrhea is higher in women than in men. According to the Centers for Disease Control (CDC), it is estimated that among these 8,20,000 new cases, 70% of the population would be between the ages of 15 and 24. The Centers for Disease Control (CDC) reports that gonorrhea is more likely to affect women over the age of 25.


    Gonorrhea Diagnostics Market Challenge


    Rise of Antibiotic-resistant Gonococcal Strains:


      The Centers for Disease Control (CDC) restricted the use of fluoroquinolones in the U.S. as a result of the spread of fluoroquinolone-resistant Neisseria gonorrhoeae, leaving cephalosporin as the main risk-free agent for gonorrheal infection. As per the Centers for Disease Control (CDC), there are around 400,000 cases of gonorrhea reported each year in the U.S. and approximately 8,20,000 new gonorrhea infections might occur each year. Out of these, about 30% of new infections are resistant to at least one antibiotic intended to treat the infection. This narrows the range of therapy options available to patients, thereby hindering Gonorrhea Diagnostics market growth.


      Gonorrhea Diagnostics Industry Outlook:


      Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Gonorrhea Diagnostics Industry. The top 10 companies in the Gonorrhea Diagnostics Industry are:

      1. Abbott Laboratories
      2. Bayer AG
      3. Merck & Co., Inc.
      4. Agilent Technologies
      5. Biomerieux SA
      6. Danaher Corporation
      7. Thermo Fisher Scientific
      8. DiaSorin
      9. Bristol-Myers Squibb
      10. F. Hoffmann-La Roche

      Recent Developments


      • In October 2022, Bayer and the Bill & Melinda Gates Foundation are jointly funding pre-clinical research in the area of novel non-hormonal contraception. This collaboration with the Bill & Melinda Gates Foundation would contribute to expanding access to contraceptive options that address the unmet needs of women worldwide.
      • In September 2022, Abbott launched its European Amplatzer™ Talisman™ PFO Occlusion System to treat people who have had a stroke and are at risk of getting another one and have a Patent Foramen Ovale (PFO), a hole in the heart that doesn't shut after birth.
      • In August 2022, Danaher Corporation announced the completion of its acquisition of Aldevron. It would operate as a standalone operating company and brand within Danaher's Life Sciences segment.

      Relevant Titles

      Diagnostic Imaging Services Market - Industry Analysis, Market Size, Market Share, Trend Analysis, Application Analysis and Forecast Analysis.


      Report Code: HCR 0248


      E. Coli Testing Market - Industry Analysis, Market Size, Market Share, Trend Analysis, Application Analysis and Forecast Analysis.


      Report Code: HCR 0285


      Infectious Disease Testing Market - Industry Analysis, Market Size, Market Share, Trend Analysis, Application Analysis and Forecast Analysis.

      Report Code: HCR 0085

      Comments

      Post a Comment

      Popular posts from this blog

      Narcolepsy Market - Forecast(2022 - 2027)

        Narcolepsy Market size is estimated to be $2.68 billion in 2019, growing at a CAGR of 10.4% during the forecast period 2020-2025.Increasing obese population and rising prevalence of narcolepsy is a major factor driving the narcolepsy market during the forecast period 2020-2025.Futhermore, narcolepsy is a lifelong nervous system disorder that effect a person quality of life. Moreover, according to the Narcolepsy Network narcolepsy affected an estimated 1 in every 2000 people in the U.S. That’s 2000,000 Americans and approximately 3 million worldwide. Furthermore, people suffering from narcolepsy frequently enter into cataplexy and REM sleep within every 15 minutes of falling asleep, thereby driving the demand of proper narcolepsy treatment which in turn is boosting the narcolepsy market. In addition sleep apnea symptoms are similar to narcolepsy and patients go through excessive daytime sleepiness (EDS) thereby raising the demand of narcolepsy treatment. Request Sample Report Coverag
      Read more

      Postmenopausal Hormone Therapy Market Forecast (2022-2027)

      Image
        Postmenopausal Hormone Therapy Market size is estimated   to reach $46.5 billion   by 2027, growing   at a CAGR of 5.1%   during the forecast period 2022-2027. Postmenopausal Hormone Therapy includes medicines covering female hormones to take the place of the once the body no longer makes subsequent to menopause and is occasionally utilized to treat typical menopausal symptoms, inclusive of hot flashes and vaginal discomfort. Hormone therapy has also been confirmed to avert bone loss and decrease fractures in postmenopausal women. Atrophic vaginitis is normally associated with menopause and the related depleted levels of estrogen. Bazedoxifene is a novel SERM (Selective Estrogen Receptor Modulator) established by Wyeth Pharmaceuticals that is presently in phase III clinical trials for the avoidance and treatment of postmenopausal osteoporosis. Phytoestrogens are organic constituents from plants that bind to estrogen receptors in the body. Download Report Sample The proliferating pop
      Read more